134 related articles for article (PubMed ID: 30807559)
1. Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Lima CMSR
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):3-5. PubMed ID: 30807559
[No Abstract] [Full Text] [Related]
2. Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Yu K
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):9-10. PubMed ID: 30807562
[No Abstract] [Full Text] [Related]
3. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560
[No Abstract] [Full Text] [Related]
4. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
5. New guideline-sanctioned and emerging interventions for pancreatic cancer.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):7-9. PubMed ID: 30807561
[No Abstract] [Full Text] [Related]
6. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
[TBL] [Abstract][Full Text] [Related]
8. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Bockorny B; Macarulla T; Semenisty V; Borazanci E; Feliu J; Ponz-Sarvise M; Abad DG; Oberstein P; Alistar A; Muñoz A; Geva R; Guillén-Ponce C; Fernandez MS; Peled A; Chaney M; Gliko-Kabir I; Shemesh-Darvish L; Ickowicz D; Sorani E; Kadosh S; Vainstein-Haras A; Hidalgo M
Clin Cancer Res; 2021 Sep; 27(18):5020-5027. PubMed ID: 34253578
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Salvia R; Malleo G; Maggino L; Milella M; Bassi C
Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
[No Abstract] [Full Text] [Related]
10. Combined treatment for locally advanced pancreatic cancer.
Das M
Lancet Oncol; 2019 Jul; 20(7):e351. PubMed ID: 31178373
[No Abstract] [Full Text] [Related]
11. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
Wang M; Zhu P; Chen Z; Yang L
Anticancer Drugs; 2022 Jan; 33(1):e686-e691. PubMed ID: 34459461
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Wu AA; Bever KM; Ho WJ; Fertig EJ; Niu N; Zheng L; Parkinson RM; Durham JN; Onners B; Ferguson AK; Wilt C; Ko AH; Wang-Gillam A; Laheru DA; Anders RA; Thompson ED; Sugar EA; Jaffee EM; Le DT
Clin Cancer Res; 2020 Oct; 26(19):5129-5139. PubMed ID: 32591464
[TBL] [Abstract][Full Text] [Related]
13. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
14. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Cinar P; Ko AH
Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
[TBL] [Abstract][Full Text] [Related]
15. BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
Kondo T; Kanai M; Matsubara J; Quy PN; Fukuyama K; Yamamoto Y; Yamada T; Nishigaki M; Minamiguchi S; Takeda M; Nishio K; Matsumoto S; Muto M
Pancreas; 2020; 49(10):e101-e103. PubMed ID: 33017331
[No Abstract] [Full Text] [Related]
16. [Diagnostics and therapy of pancreatic carcinoma].
Wenzel P; von Figura G
Dtsch Med Wochenschr; 2021 Feb; 146(4):246-252. PubMed ID: 33592660
[TBL] [Abstract][Full Text] [Related]
17. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Usón Junior PLS; Rother ET; Maluf FC; Bugano DDG
Clin Colorectal Cancer; 2018 Sep; 17(3):187-197. PubMed ID: 29615310
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous regression of pancreatic cancer with liver metastases.
Saade Lemus P; Anderson K; Smith M; Bullock A
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31154349
[TBL] [Abstract][Full Text] [Related]
20. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]